Crossref
How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia?
Journal of Hematology and Blood Disorders · 2018
DOI: 10.15744/2455-7641.4.103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hematology and Blood Disorders, 2018. Verfasst von Nakaya A und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
A, N., S, F., A, S., T, N., Y, A., Y, T., A, K., M, H., H, Y., K, I., T, I., & S, N. (2018). How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia?. Journal of Hematology and Blood Disorders. https://doi.org/10.15744/2455-7641.4.103
Vancouver
A N, S F, A S, T N, Y A, Y T, et al. How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia?. Journal of Hematology and Blood Disorders. 2018. doi:10.15744/2455-7641.4.103
BibTeX
@article{A2018,
author = {A, Nakaya and S, Fujita and A, Satake and T, Nakanishiq and Y, Azuma and Y, Tsubokura and A, Konishi and M, Hotta and H, Yoshimura and K, Ishii and T, Ito and S, Nomura},
title = {How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia?},
journal = {Journal of Hematology and Blood Disorders},
year = {2018},
doi = {10.15744/2455-7641.4.103}
}
EUVIMED